Abbott receives fda approval for world's first dual-chamber leadless pacemaker

Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a aaa battery leadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the u.s. who need pacing to treat a variety of slow or abnormal heart rhythms approval comes on the heels of recent late-breaking clinical trial data showing that the aveir™ dr leadless pacemaker system is safe and effective at treating abnormal heart rhythms abbott park, ill., july 5, 2023 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved the aveir™ dual chamber (dr) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.
ABT Ratings Summary
ABT Quant Ranking